BTZ and its derivatives are used clinically to treat several types of blood cancers, associated with a multitude of side effects due to the proteasome’s essential function in all cells (Deshaies, 2014; Manasanch and Orlowski, 2017; Zhang et al, 2020). This evidence concerns the gene CASC3 and hematopoietic and lymphoid system neoplasm.